Outpatient Therapeutics

February 26, 2024
Outpatient Therapeutics DOH Issues Advisory on Underutilization of COVID-19 Antivirals: COVID-19 antivirals remain underutilized in high-risk populations.; Read More

February 20, 2024
Outpatient Therapeutics DOH Advisory: COVID-19 Antiviral Treatment Underutilization and Changes in How to Access Medications with Commercialization of Oral Antivirals: Read More

January 31, 2023
Outpatient Therapeutics DOH Issues Revised Guidance on COVID-19 Treatment Recommendations: Members encouraged to share information with their medical directors and physicians.; Read More

January 26, 2023
Outpatient Therapeutics DOH Advisory: Updates on COVID-19 Treatment Recommendations: Read More

November 30, 2022
Outpatient Therapeutics DOH Advisory: Updates on COVID-19 Treatment Recommendations: Read More

May 31, 2022
Outpatient Therapeutics DOH Issues Health Advisory Regarding Paxlovid Use: Advisory relates to use of Paxlovid and potential for rebound COVID-19 after treatment.; Read More

May 24, 2022
Outpatient Therapeutics DOH Advisory: COVID-19 Rebound After Paxlovid Treatment: Read More

April 25, 2022
Outpatient Therapeutics Access to COVID-19 Therapeutics: Reminders for Nursing Homes: Nursing homes that operate their own pharmacy must enroll in a specialized system to request monoclonal antibody therapies and may request oral antivirals by sending a request to covid19therapeutics@health.ny.gov or through the Health Partner Order Portal. Nursing homes that do not operate their own pharmacy may access therapeutics through their LTC pharmacy.; Read More

April 19, 2022
Outpatient Therapeutics DOH Advisory: COVID-19 Oral Antiviral Treatment Available: Read More

March 29, 2022
Outpatient Therapeutics DOH Issues Advisory on Pause in Distribution of Sotrovimab: Currently authorized alternative treatments, including Paxlovid, molnupiravir, and bebtelovimab, available for distribution.; Read More